SLS logo
SLS NASDAQ US

SELLAS Life Sciences Group, Inc. - Common Stock

Healthcare · Biotechnology Website · IPO Mar 2008
$4.13
▼ $-0.08 (-1.90%)
Vol 4.8M
4
Quality Score
fail
Mkt Cap
$537.0M
ROE
-95.2%
Margin
-736.2%
D/E
0.00
Beta
2.46
52W
$1–$3

Wall Street Consensus

7 analysts · Apr 2026
2
Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating

Price Chart

Similar Stocks

ANNX
Annexon Inc
$726.5M
MNKD
MannKind Corp
P/E 60.5
$1.7B
JBIO
Jade Biosciences Inc
$709.8M
KURA
Kura Oncology Inc
$904.1M
VOR
Vor Biopharma Inc
$286.6M
MGTX
MeiraGTx Holdings PLC
$639.9M
SLDB
Solid Biosciences Inc
$439.4M
BBOT
BridgeBio Oncology Therapeutics Inc
P/E 212.3
$1.0B

Earnings

Beat rate: 100.0%
Next Report May 11, 2026
EPS Estimate: $-0.05
Quarter EPS Est EPS Act Surprise
Mar 2026 $-0.05 — —
Dec 2025 $-0.07 $-0.05 +$0.02
Sep 2025 $-0.07 $-0.06 +$0.01
Jun 2025 $-0.08 $-0.07 +$0.01

Fundamentals Trend

Metric 2025-06-30 2025-09-02 2025-10-02 2025-11-03 2025-12-03 2026-01-02
ROE (TTM) -132.5% -193.7% -132.5% -132.5% -132.5% -95.2%
P/E (TTM) — — — — — —
Net Margin — -736.2% -736.2% -736.2% -736.2% -736.2%
Gross Margin — 93.1% 93.1% 93.1% 93.1% 93.1%
D/E Ratio 0.00 0.00 0.00 0.00 0.00 0.00
Current Ratio 4.91 4.64 4.91 4.91 4.91 8.28

Key Ratios

ROA (TTM)
-75.1%
P/S (TTM)
185.17
P/B
7.7
EPS (TTM)
$-0.29
CF/Share
$-0.36
52W High
$3.01
52W Low
$0.85
$0.85 52-Week Range $3.01

How does SLS compare to Biotechnology peers?

Peer group: Micro-cap Biotechnology (All) · 528 companies

SLS AAPG ABEO ABOS ABP

SLS valuation vs Biotechnology peers

P/E ratio
—
▼ 0% below peers (18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
185.2
▲ 1341% above peers (12.9)
vs Peers
vs Industry
Pricier
P/B ratio
7.7
▲ 214% above peers (2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼ 0% below peers (0.0%)
vs Peers
vs Industry
Low yield

SLS profitability vs Biotechnology peers

ROE
-95.2%
▼ 41% below peers (-67.3%)
vs Peers
vs Industry
Weak
Net margin
-736.2%
▼ 157% below peers (-286.8%)
vs Peers
vs Industry
Weak
Gross margin
93.1%
▲ 18% above peers (78.6%)
vs Peers
vs Industry
Weak
ROA
-75.1%
▼ 61% below peers (-46.7%)
vs Peers
vs Industry
Weak

SLS financial health vs Biotechnology peers

D/E ratio
0.0
▼ 0% below peers (0.0)
vs Peers
vs Industry
Low debt
Current ratio
8.3
▲ 86% above peers (4.4)
vs Peers
vs Industry
Strong liquidity
Beta
2.5
▲ 154% above peers (1.0)
vs Peers
vs Industry
More volatile

SLS fundamentals radar

SLS Peer median Industry

SLS profitability vs leverage

Bubble size = market cap · X = net margin · Y = D/E ratio

SLS vs peers: key metrics

Latest News

NASA May Shrink Boeing's Moon-Mission Role While Handing SpaceX Core Rocket Responsibilities
ZeroHedge · Mar 20